Premium
Melanoma and non‐melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30‐year experience at Memorial Sloan Kettering Cancer Center
Author(s) -
Watts Justin M.,
Kishtagari Ashwin,
Hsu Meier,
Lacouture Mario E.,
Postow Michael A.,
Park Jae H.,
Stein Eytan M.,
TeruyaFeldstein Julie,
AbdelWahab Omar,
Devlin Sean M.,
Tallman Martin S.
Publication year - 2015
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.13528
Subject(s) - medicine , melanoma , skin cancer , vemurafenib , cancer , incidence (geometry) , population , surveillance, epidemiology, and end results , oncology , epidemiology , dermatology , cancer research , cancer registry , metastatic melanoma , physics , environmental health , optics
Summary Few studies have examined melanoma and non‐melanoma skin cancer ( NMSC ) incidence rates after a diagnosis of hairy cell leukaemia ( HCL ). We assessed 267 HCL patients treated at Memorial Sloan Kettering Cancer Center ( MSKCC ) and Surveillance, Epidemiology and End Results ( SEER ) data for melanoma and NMSC incidence rates after HCL . Incidence data from MSKCC patients demonstrated a 10‐year combined melanoma and NMSC skin cancer rate of 11·3%, melanoma 4·4% and NMSC 6·9%. Molecular analysis of skin cancers from MSKCC patients revealed activating RAS mutations in 3/9 patients, including one patient with melanoma. Of 4750 SEER patients with HCL , 55 (1·2%) had a subsequent diagnosis of melanoma. Standardized incidence ratios ( SIR s) did not show that melanoma was more common in HCL patients versus the general population ( SIR 1·3, 95% CI 0·78–2·03). Analysis of SEER HCL patients diagnosed before and after 1990 (approximately before and after purine analogue therapy was introduced) showed no evidence of an increased incidence after 1990. A better understanding of any potential association between HCL and skin cancer is highly relevant given ongoing trials using BRAF inhibitors, such as vemurafenib, for relapsed HCL , as RAS ‐mutant skin cancers could be paradoxically activated in these patients.